Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.
Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C, Cote J, Bray G, Fujioka K, Bays H, Hollander P, Sanabria-Bohórquez SM, Eng W, Långström B, Hargreaves RJ, Burns HD, Kanatani A, Fukami T, MacNeil DJ, Gottesdiener KM, Amatruda JM, Kaufman KD, Heymsfield SB. Erondu N, et al. Among authors: macneil dj. Cell Metab. 2006 Oct;4(4):275-82. doi: 10.1016/j.cmet.2006.08.002. Cell Metab. 2006. PMID: 17011500 Free article. Clinical Trial.
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults.
Gantz I, Erondu N, Mallick M, Musser B, Krishna R, Tanaka WK, Snyder K, Stevens C, Stroh MA, Zhu H, Wagner JA, Macneil DJ, Heymsfield SB, Amatruda JM. Gantz I, et al. Among authors: macneil dj. J Clin Endocrinol Metab. 2007 May;92(5):1754-7. doi: 10.1210/jc.2006-1806. Epub 2007 Mar 6. J Clin Endocrinol Metab. 2007. PMID: 17341568 Clinical Trial.
A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice.
Ishihara A, Kanatani A, Mashiko S, Tanaka T, Hidaka M, Gomori A, Iwaasa H, Murai N, Egashira S, Murai T, Mitobe Y, Matsushita H, Okamoto O, Sato N, Jitsuoka M, Fukuroda T, Ohe T, Guan X, MacNeil DJ, Van der Ploeg LH, Nishikibe M, Ishii Y, Ihara M, Fukami T. Ishihara A, et al. Among authors: macneil dj. Proc Natl Acad Sci U S A. 2006 May 2;103(18):7154-8. doi: 10.1073/pnas.0510320103. Epub 2006 Apr 24. Proc Natl Acad Sci U S A. 2006. PMID: 16636293 Free PMC article.
A pair-feeding study reveals that a Y5 antagonist causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure.
Mashiko S, Ishihara A, Iwaasa H, Sano H, Ito J, Gomori A, Oda Z, Moriya R, Matsushita H, Jitsuoka M, Okamoto O, MacNeil DJ, Van der Ploeg LH, Fukami T, Kanatani A. Mashiko S, et al. Among authors: macneil dj. Mol Pharmacol. 2007 Feb;71(2):602-8. doi: 10.1124/mol.106.029991. Epub 2006 Nov 14. Mol Pharmacol. 2007. PMID: 17105869
Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine.
Mashiko S, Ishihara A, Iwaasa H, Moriya R, Kitazawa H, Mitobe Y, Ito J, Gomori A, Matsushita H, Takahashi T, MacNeil DJ, Van der Ploeg LH, Fukami T, Kanatani A. Mashiko S, et al. Among authors: macneil dj. Obesity (Silver Spring). 2008 Jul;16(7):1510-5. doi: 10.1038/oby.2008.223. Epub 2008 Apr 10. Obesity (Silver Spring). 2008. PMID: 18421274 Free article.
L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist.
Kanatani A, Ishihara A, Iwaasa H, Nakamura K, Okamoto O, Hidaka M, Ito J, Fukuroda T, MacNeil DJ, Van der Ploeg LH, Ishii Y, Okabe T, Fukami T, Ihara M. Kanatani A, et al. Among authors: macneil dj. Biochem Biophys Res Commun. 2000 May 27;272(1):169-73. doi: 10.1006/bbrc.2000.2696. Biochem Biophys Res Commun. 2000. PMID: 10872822
101 results